Literature DB >> 32992245

COVID-19 therapy: What weapons do we bring into battle?

Sinara Mônica Vitalino de Almeida1, José Cleberson Santos Soares2, Keriolaine Lima Dos Santos2, Josival Emanuel Ferreira Alves3, Amélia Galdino Ribeiro2, Íris Trindade Tenório Jacob2, Cindy Juliane da Silva Ferreira4, Jéssica Celerino Dos Santos4, Jamerson Ferreira de Oliveira2, Luiz Bezerra de Carvalho Junior3, Maria do Carmo Alves de Lima2.   

Abstract

Urgent treatments, in any modality, to fight SARS-CoV-2 infections are desired by society in general, by health professionals, by Estate-leaders and, mainly, by the scientific community, because one thing is certain amidst the numerous uncertainties regarding COVID-19: knowledge is the means to discover or to produce an effective treatment against this global disease. Scientists from several areas in the world are still committed to this mission, as shown by the accelerated scientific production in the first half of 2020 with over 25,000 published articles related to the new coronavirus. Three great lines of publications related to COVID-19 were identified for building this article: The first refers to knowledge production concerning the virus and pathophysiology of COVID-19; the second regards efforts to produce vaccines against SARS-CoV-2 at a speed without precedent in the history of science; the third comprehends the attempts to find a marketed drug that can be used to treat COVID-19 by drug repurposing. In this review, the drugs that have been repurposed so far are grouped according to their chemical class. Their structures will be presented to provide better understanding of their structural similarities and possible correlations with mechanisms of actions. This can help identifying anti-SARS-CoV-2 promising therapeutic agents.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiviral; COVID-19; Coronavirus; Repurposed drugs; SARS-CoV-2

Year:  2020        PMID: 32992245      PMCID: PMC7481143          DOI: 10.1016/j.bmc.2020.115757

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  GC-MS, LC-MS/MS, Docking and Molecular Dynamics Approaches to Identify Potential SARS-CoV-2 3-Chymotrypsin-Like Protease Inhibitors from Zingiber officinale Roscoe.

Authors:  Muhammad Sulaiman Zubair; Saipul Maulana; Agustinus Widodo; Ramadanil Pitopang; Muhammad Arba; Maywan Hariono
Journal:  Molecules       Date:  2021-08-28       Impact factor: 4.927

2.  Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.

Authors:  Marcella Ricardis May; Albert Rübben; Andrea Lennertz; Luk Vanstreels; Marike Leijs
Journal:  J Pers Med       Date:  2022-01-27

Review 3.  Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.

Authors:  Dingzhong Li; Jianbing Hu; Dian Li; Weijun Yang; Shuang-Feng Yin; Renhua Qiu
Journal:  Top Curr Chem (Cham)       Date:  2021-01-11

Review 4.  Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.

Authors:  Paul Andrei Negru; Andrei-Flavius Radu; Cosmin Mihai Vesa; Tapan Behl; Mohamed M Abdel-Daim; Aurelia Cristina Nechifor; Laura Endres; Manuela Stoicescu; Bianca Pasca; Delia Mirela Tit; Simona Gabriela Bungau
Journal:  Biomed Pharmacother       Date:  2022-02-04       Impact factor: 6.529

Review 5.  An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.

Authors:  H S C Paula; S B Santiago; L A Araújo; C F Pedroso; T A Marinho; I A J Gonçalves; T A P Santos; R S Pinheiro; G A Oliveira; K A Batista
Journal:  Braz J Med Biol Res       Date:  2021-12-10       Impact factor: 2.590

6.  Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives.

Authors:  Bo Jin; Jia-Yi Chen; Zun-Lai Sheng; Meng-Qing Sun; Hong-Liang Yang
Journal:  Molecules       Date:  2022-02-07       Impact factor: 4.411

7.  Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods.

Authors:  I D Konstantinova; V L Andronova; I V Fateev; R S Esipov
Journal:  Acta Naturae       Date:  2022 Apr-Jun       Impact factor: 2.204

8.  Derivatives of benzo-1,4-thiazine-3-carboxylic acid and the corresponding amino acid conjugates.

Authors:  Péter Kisszékelyi; Tibor Peňaška; Klára Stankovianska; Mária Mečiarová; Radovan Šebesta
Journal:  Beilstein J Org Chem       Date:  2022-09-09       Impact factor: 2.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.